Dr Michele Maio talks with ecancer at the 2013 European Cancer Congress in Amsterdam about the survival analysis of a phase III study of ipilimumab and dacarbazine in metastatic melanoma

The results of this study, with 5 years of follow up, continue to demonstrate a long-term survival benefit for patients treated with ipilimumab plus DTIC compared to placebo plus DTIC. Consistent with the results of phase II studies, survival rates appear to plateau beginning at 3 years.

Dr Keith Flaherty provides additional commentary on the study